^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TPIV200
i
Other names: folate receptor alpha-loaded dendritic cell vaccine, folate receptor alpha vaccine, TPIV 200, TPIV-200, TPIV200, multiple epitope folate receptor alpha peptide vaccine, FR alpha peptide vaccine, TPIV200/huFR-1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Marker Therap, Mayo Clinic
Drug class:
Folate receptor 1 inhibitor, Folate receptor 2 inhibitor
Related drugs:
4ms
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial. (PubMed, Gynecol Oncol)
TPIV200 was well tolerated but was not associated with improved PFS. Additional studies are required to uncover potential synergies using multiepitope vaccines targeting FRα. Trial Registration NLM/NCBI Registry, NCT02978222, https://clinicaltrials.gov/search?term=NCT02978222.
Clinical • Journal
|
FOLR1 ( Folate receptor alpha ) • CSF2 (Colony stimulating factor 2)
|
TPIV200
over3years
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=80, Completed, Marker Therapeutics, Inc. | Active, not recruiting --> Completed
Clinical • Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
TPIV200 • cyclophosphamide intravenous
over3years
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=80, Active, not recruiting, Marker Therapeutics, Inc. | Trial completion date: Dec 2021 --> Aug 2021 | Trial primary completion date: Dec 2021 --> Aug 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
TPIV200 • cyclophosphamide intravenous
over4years
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. (PubMed, J Immunother Cancer)
Combination of TPIV200 and durvalumab was safe and elicited robust FRα-specific T cell responses in all patients. Unexpectedly durable survival in this heavily pretreated population highlights the need to investigate the impact of FRα vaccination on the OC biology post-treatment.
Clinical • P2 data • Journal • Combination therapy • PD(L)-1 Biomarker
|
FOLR1 ( Folate receptor alpha ) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • TPIV200
over4years
[VIRTUAL] A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC). (ASCO 2020)
Although TPIV200 had a manageable safety profile, the study was terminated for futility after the planned interim analysis. Future development of FRα-targeted therapy will likely focus on the careful selection of patients whose cancers show high FRα expression. Research Funding: Marker Therapeutics, Inc.
Clinical • P2 data
|
FOLR1 ( Folate receptor alpha ) • CSF2 (Colony stimulating factor 2)
|
TPIV200
Share via
